Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Luke Evnin
AddedMar 31, 2024
UpdatedMay 31, 2026
Luke Evnin

Luke Evnin

Board Member, DigiTx Partners

Crunchbase

Luke Evnin's Career

DigiTx Partners
DigiTx Partners

Brisbane, CA, US

Board Member· Board
MPM Capital
MPM Capital

Boston, MA, US

Co-Founder
Werewolf Therapeutics
Werewolf Therapeutics

Watertown, WI, US

Board Member· Board
NeuroTherapeutics Pharma
NeuroTherapeutics Pharma

Chicago, IL, US

Board Member· Board
Amphivena Therapeutics
Amphivena Therapeutics

California, US

Founder
Peptimmune
Peptimmune

Cambridge, MA, US

Board Member· Board
Blade Therapeutics
Blade Therapeutics

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Luke Evnin's Career

DigiTx Partners
DigiTx Partners
Investment FirmInvestment Firm82016Brisbane, CA, US
Board Member· Board

Leadership at DigiTx Partners

David J. KimDavid J. KimBoard Member
Yutaka WatanabeYutaka WatanabeBoard Member
MPM Capital
MPM Capital
Investment FirmInvestment Firm301996Boston, MA, US
Co-Founder

Leadership at MPM Capital

Ansbert GadickeAnsbert GadickeCo-Founder

Similar to MPM Capital

MP Healthcare Venture ManagementMP Healthcare Venture ManagementBoston, MA, USest. 2006MP Healthcare Venture ManagementBoston, MA, US · est. 2006

MP Healthcare Venture Management: A US-based venture capital firm investing in biotech and healthcare sectors.

Investment Firm7
BioImpact CapitalBioImpact CapitalBoston, MA, USest. 2015BioImpact CapitalBoston, MA, US · est. 2015

BioImpact Capital: Investing in biotech startups to address unmet medical needs.

Investment Firm30
MVM PartnersMVM PartnersLondon, Greater London, GBest. 2005MVM PartnersLondon, Greater London, GB · est. 2005

MVM Life Science Partners: A global venture capital firm investing in healthcare and pharmaceutical sectors.

Investment Firm35
Foresite CapitalForesite CapitalSan Francisco, CA, USest. 2011Foresite CapitalSan Francisco, CA, US · est. 2011

Foresite Capital: A leading US venture capital & growth equity firm, headquartered in San Francisco.

Investment Firm68
Werewolf Therapeutics
Werewolf Therapeutics
Public$128.2M502017Watertown, WI, US
Board Member· Board

Leadership at Werewolf Therapeutics

Patrick BaeuerlePatrick BaeuerleCo-Founder
K. Dane WittrupK. Dane WittrupBoard Member
Mike ShermanMike ShermanBoard Member
Meeta ChatterjeeMeeta ChatterjeeBoard Member
Dan HicklinDan HicklinBoard Member

Similar to Werewolf Therapeutics

PanTher TherapeuticsPanTher TherapeuticsWatertown, MA, USCancer Treatmentest. 2016PanTher TherapeuticsWatertown, MA, US · est. 2016

PanTher Therapeutics: Revolutionizing cancer care with an effective, minimal side-effect treatment platform.

Series B · $21.3M13
Window TherapeuticsWindow TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4
Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
NeuroTherapeutics Pharma
NeuroTherapeutics Pharma
Public$60.7M302006Chicago, IL, US
Board Member· Board

Leadership at NeuroTherapeutics Pharma

Corey GoodmanCorey GoodmanBoard Member
Stephen CollinsStephen CollinsBoard Member
Fran HellerFran HellerBoard Member
Dr Thomas R Beck \"Tom\"Dr Thomas R Beck \"Tom\"Board Member
Christine E SiuChristine E SiuBoard Member
Elaine V. JonesElaine V. JonesBoard Member
Amphivena Therapeutics
Amphivena Therapeutics
Series C$135.7M172012California, US
Founder

Leadership at Amphivena Therapeutics

Curtis RueggCurtis RueggBoard Member
Peter Van VlasselaerPeter Van VlasselaerBoard Member
Dr Frank MuehlenbeckDr Frank MuehlenbeckBoard Member
Peptimmune
Peptimmune
Series D$92.9M302002Cambridge, MA, US
Board Member· Board

Leadership at Peptimmune

Fredric PriceFredric PriceBoard Member
Dr M James Barrett \"Jim\"Dr M James Barrett \"Jim\"Board Member

Similar to Peptimmune

InimmuneInimmuneMissoula, MT, USImmunotherapeuticsest. 2016InimmuneMissoula, MT, US · est. 2016

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15
PeptiMedPeptiMedMadison, WI, USTherapeutic Drugsest. 2012PeptiMedMadison, WI, US · est. 2012

PeptiMed, Inc.: A biotech firm developing targeted therapeutic drugs for advanced cancers in the US.

Seed · $500k6
Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
IpiNovyx BioIpiNovyx BioWest Nyack, NY, USTherapeuticsest. 2021IpiNovyx BioWest Nyack, NY, US · est. 2021

IpiNovyx Bio: Pioneering immunoproteasome therapeutics for autoimmune and inflammatory diseases.

Seed · $10M6
Blade Therapeutics
Blade Therapeutics
Series D$51.5M282013South San Francisco, CA, US
Board Member· Board

Leadership at Blade Therapeutics

Wendye RobbinsWendye RobbinsCEO
Mark TimneyMark TimneyBoard Member
Jim ScopaJim ScopaBoard Member
Rana Al-HallaqRana Al-HallaqBoard Member
Harry DietzHarry DietzFounder

Similar to Blade Therapeutics

Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Mistral TherapeuticsMistral TherapeuticsSan Diego, CA, USFibrosis Treatmentsest. 2011Mistral TherapeuticsSan Diego, CA, US · est. 2011

Mistral Therapeutics: A San Diego-based biotech firm specializing in innovative fibrosis treatments.

Series B · $36.4M6
BLR BioBLR BioKenosha, WI, USBiologics, Diagnosticsest. 2013BLR BioKenosha, WI, US · est. 2013

Kenosha-based BLR Bio, a private biotech firm, specializes in orphan and specialty fibrotic diseases.

Pre-Seed · $780k5

Luke Evnin's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Luke Evnin

Ed HurwitzEd HurwitzBoard Member · MacroGenicsTodd FoleyTodd FoleyBoard Member · Tetherex PharmaceuticalsBrandon RomanekBrandon RomanekFounder · Millennium BlockchainWoody MarshallWoody MarshallBoard Member · Payoneer GlobalPhilip KrimPhilip KrimCo-Founder · CasperStephen Evans-FrekeStephen Evans-FrekeBoard Member · Lakewood-Amedex Biotherapeutics